Drugs / Tigulixostat
Tigulixostat
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04966325 | Sep → Dec 2021 | gout | LG Chem | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT06189404 | Oct → Nov 2023 | gout | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT04070846 | Feb → Mar 2020 | gout | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT04139824 | Jan → Feb 2020 | gout | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT04066712 | Nov 2019 → Sep 2020 | gout | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT03927677 | Nov 2019 | gout | LG Chem | Completed | No outcome recorded |
| Phase 1 | NCT01361646 | Jun 2011 → Jan 2013 | gout | LG Life Sciences | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03934099 | Dec 2019 → May 2021 | gout | LG Chem | Completed | Met primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT07414394 | Mar 2026 → Apr 2027 expected | gout | Innovent Biologics Technology Limited (Shanghai R&D Center) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05586971 | Mar 2023 → May 2025 | gout | LG Chem | Completed | No outcome recorded |
| Phase 3 | NCT05586958 | Oct 2022 → Nov 2024 | gout | LG Chem | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04886050 Comparator | Jul → Sep 2021 | gout | LG Chem | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-09-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress innoventbio.com ↗
Tigulixostat demonstrated significantly greater urate-lowering efficacy and favorable safety profiles compared to febuxostat across all dose groups. |
| 2022-08-01 | LG Life Sciences | Regulatory LG Chem Begins Final Clinical Stage for New Gout Medicine lgchem.com ↗
LG Chem announced that it applied for clinical phase 3 test plans for its independently developed new gout medicine ‘Tigulixostat’ (research project name; EURELIA_1 Study) to the US FDA on the 1st. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-23 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study innoventbio.com ↗ |
| 2025-09-08 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress innoventbio.com ↗ |
| 2022-12-15 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease innoventbio.com ↗ |
| 2022-08-01 | LG Life Sciences | LG Chem Begins Final Clinical Stage for New Gout Medicine lgchem.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tigulixostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07414394 ↗ |
| Known as | IBI128 | “Participants in this group receive Tigulixostat (IBI128) tablets together with dummy tablets matching Febuxostat once daily during the 24-week core treatment period, with dose...” NCT07414394 ↗ |
| Known as | LC350189 | “LC350189 200mg qd” NCT04139824 ↗ |
| Action | Inhibit | “Xanthine Oxidase Inhibitor” NCT03934099 ↗ |
| Modality | Small molecule | — CHEMBL3652780 ↗ |
| Route | Oral | “by oral” NCT04066712 ↗ |